Loading company…
Seoul-based drug developer using AI platforms such as RAPTOR AI to find therapies for oncology and rare diseases.
Founded in 2015 and headquartered in Seoul, South Korea, ONCOCROSS develops drugs using artificial intelligence, focusing on oncology and rare diseases. Its ONCOCROSS AI Platform includes RAPTOR AI, ONCO-RAPTOR AI and ONCOfind AI, and it works with pharmaceutical partners and research institutions. In a PRE-IPO round on December 18, 2024, it raised KRW 10.4 billion from Dongwha Pharmaceutical, InterVest, Moru Asset Management, Pathfinder H and ST Capital, and its CEO is Yi-rang Kim.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in